Baird Maintains Outperform on Allogene Therapeutics, Raises Price Target to $9

Benzinga Newsdesk www.benzinga.com Positive 88.4%

Neg 0% Neu 0% Pos 88.4%

Baird analyst Jack Allen maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and raises the price target from $7 to $9.